Trending Articles

article thumbnail

Pharmacist Outreach Reduces Therapeutic Inertia in T2D | ADA 2025

Drug Topics

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

315
315
article thumbnail

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

PharmaVoice

Skip to main content CONTINUE TO SITE ➞ Dont miss the most important voices in pharma Let PharmaVoices free newsletter keep you informed on what industry leaders are saying, straight from your inbox. By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Deve

Packaging 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CVS Under Investigation for Text Messages Lobbying Against Louisiana PBM Reform

Drug Topics

Louisiana opened the investigation upon discovering a CVS text message campaign sent out to patients asking them to advocate against proposed legislation.

541
541
article thumbnail

FDA to speed reviews for drugs supporting ‘national interests’

PharmaVoice

A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

FDA 219
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

New report finds rampant abuse of the 340B program

PhRMA

A new analysis from ADVI shows how the federal government routinely neglected to provide oversight of the 340B program. While 99.7% of 340B providers escape scrutiny due to a lack of oversight, the majority of audits that are conducted reveal adverse findings, raising serious concerns.

147
147
article thumbnail

Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr.

STAT

WASHINGTON — A key Senate health leader is calling for this week’s meeting of the panel of vaccine advisers handpicked by Health and Human Services Secretary Robert F. Kennedy Jr. to be delayed, citing their lack of experience and potential bias against some vaccines. “Although the appointees to [the Advisory Committee on Immunization Practices] have scientific credentials, many do not have significant experience studying microbiology, epidemiology or immunology.

Vaccines 145

More Trending

article thumbnail

FDA Approves Nitisinone for Treatment of Alkaptonuria

Drug Topics

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

FDA 341
article thumbnail

What to know about vaccine ingredients: Aluminum and thimerosal

PhRMA

It’s natural for people to have questions about vaccines and how each ingredient plays a role. Each ingredient included in a vaccine plays a necessary role in ensuring a vaccine’s safety, quality or effectiveness. All ingredients in vaccines are evaluated during the FDA vaccine review process and must meet rigorous safety standards.

Vaccines 147
article thumbnail

STAT+: Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access?

STAT

Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug , the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem. As far as Gilead is concerned, the groundwork exists to meet that goal. Last October, the drugmaker reached voluntary licensing agreements to eventually make lenacapavir available in 120 mostly low- and lower-middle-income countries.

126
126
article thumbnail

Can you drink coffee on Mounjaro?

The Checkup by Singlecare

If you rely on a cup (or two, or three) of coffee in the morning to jumpstart your body and mind for the day, whether or not you can continue enjoying it when starting a new medication may be one of the first questions you ask. It’s especially important when taking a long-term prescription, such as Mounjaro , a once-weekly injectable medication that treats Type 2 diabetes.

Dosage 101
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Gut Microbiome Composition Could Be Linked With Risk of Cognitive Impairment

Drug Topics

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

article thumbnail

How a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’

PharmaVoice

J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.

130
130
article thumbnail

IVIG-Glucocorticoid Combination Therapy Reduces Need for Adjunctive Immunotherapy in Pediatric MIS-C

Pharmacy Times

Glucocorticoids alone were found to reduce treatment failure and fever duration, but the combination with intravenous immunoglobulin (IVIG) significantly reduced the need for adjunctive immunotherapy following treatment.

97
article thumbnail

STAT+: Top drug regulator is retiring as FDA departures mount

STAT

WASHINGTON — Jacqueline Corrigan-Curay, the top drug regulator at the Food and Drug Administration, is retiring from the agency in July.  Corrigan-Curay, who took over as acting director of the Center for Drug Evaluation and Research in January, broke the news to staff in an email shared with STAT. She said she decided to leave the agency after taking a recent vacation, and thanked staff for their “unwavering support, especially during recent challenging times.

FDA 122
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Eli Lilly genetic medicine acquisition to address cardiovascular risk

European Pharmaceutical Review

Eli Lilly and Company has agreed to acquire Verve Therapeutics, Inc. in a deal set to advance genetic medicines for individuals at risk of cardiovascular disease. This acquisition has a potential total value of up to approximately $1.3 billion. Verve’s lead programme (VERVE-102) involves a potential first-in-class in vivo gene editing therapy.

92
article thumbnail

Mark Cuban Cost Plus Drugs, 9amHealth Collaborate to Make Obesity Medications Affordable

Drug Topics

News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv

article thumbnail

FDA blocks trials that send US cells to 'hostile' countries

pharmaphorum

The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as leadership at the agency in this area is sidelined.

FDA 81
article thumbnail

Expanding Pneumococcal Vaccinations to Healthy Adults Aged 50 to 64 Years Offers Significant Health, Economic Benefits

Pharmacy Times

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice in Focus: Oncology Pharmacy Practice in Focus: Health Systems Pharmacy Careers All Publications About the Publications Author Submission Submit to

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results

STAT

Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, Vertex Pharmaceuticals said Friday. After three months, none of them suffered severe bouts of low blood sugar. After 12 months, out of the 12 participants, 10 no longer needed to inject insulin.

144
144
article thumbnail

Biogen scores Cannes Festival win with dark humored campaign

PharmaVoice

The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

130
130
article thumbnail

AI Generated Marketing Campaigns: Is Pharma Ready?

Pharma Marketing Network

The intersection of artificial intelligence and pharmaceutical marketing is creating new waves of innovation. In 2025, AI generated marketing campaigns are no longer experimental. They are being deployed to personalize content, predict engagement, and automate outreach. But is the pharma industry truly ready to embrace these capabilities? Table of Contents What Are AI Generated Marketing Campaigns?

HIPAA 64
article thumbnail

How we saved our client $23,000 in five minutes

OctariusRx

Would you like to make or save a lot of money in a short period of time? Sounds like a trick question, right? We’ve often heard that if it sounds too good to be true, it probably is. In this case, we helped a client save $23,000. All it took was reviewing our benchmarking studies, a three-minute conversation and an email. Medical supplies are one of the biggest expenditures for ambulatory surgery centers.

article thumbnail

STAT+: Novo Nordisk ends deal with Hims due to compounding concerns with obesity drugs

STAT

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass compounding” of GLP-1 obesity treatments and “deceptive marketing.” Earlier this year, Novo launched a direct-to-consumer website that sells its obesity drug Wegovy at a lower price to patients who are paying on their own without insurance.

article thumbnail

Gilead's twice-yearly PrEP drug is cleared by FDA

pharmaphorum

Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

FDA 83
article thumbnail

Pharmacists Successfully Integrate with Multi-Professional Health Care Teams

Drug Topics

Researchers explored pharmacists’ ability to collaborate with other health care professionals in single-disciplinary outpatient practice environments.

341
341
article thumbnail

ASCO 2025: Real-World Outcomes of Frontline ICI Therapy in BRAF-Mutated Melanoma in the Community Setting

Pharmacy Times

Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from frontline immune checkpoint inhibitor (ICI) therapy.

article thumbnail

Neurizon confirms positive results for prospective ALS treatment

Pharmafile

Neurizon Therapeutics has announced new preclinical data confirming that NUZ-001 and its active metabolite, NUZ-001 Sulfone, effectively cross the blood-brain barrier (BBB) and reach concentrations in the brain sufficient to reverse toxic TDP-43 protein aggregation – a key driver of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).

article thumbnail

Opinion: Six former CDC vaccine advisory committee chairs warn: U.S. risks losing access to life-saving immunizations

STAT

As former chairs of the CDC’s Advisory Committee on Immunization Practices ( ACIP ), we are deeply alarmed by the growing politicization of vaccines — a public health innovation that has saved 154 million lives globally. While politicization of science is not new, the escalating distrust in science across the political spectrum, and its intrusion into the vaccine ecosystem, now threatens the very infrastructure that has long protected Americans from infectious diseases.

article thumbnail

Roche's Hemlibra follow-up set for phase 3 in haemophilia A

pharmaphorum

Roche has positive data with its follow-up to haemophilia A blockbuster Hemlibra, but a rival drug from Novo Nordisk is looming.

76
article thumbnail

Pharmacist Discusses Vaccine Guidance Uncertainty Following ACIP Removal

Drug Topics

Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, highlights the critical role pharmacists play in navigating vaccine recommendations and supporting patient understanding.

Vaccines 315
article thumbnail

Psilocybin, Ketamine, and MDMA in Cancer Care: Next Steps in Psychedelic Research

Pharmacy Times

Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.

65
article thumbnail

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for NSCLC

Pharmaceutical Technology

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

FDA 75
article thumbnail

STAT+: U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service

STAT

LONDON — A U.K. health agency reiterated on Thursday that the limited benefits of a pair of new Alzheimer’s drugs do not justify their high prices, meaning the medicines won’t be made available through the National Health Service. The decision by the U.K.’s cost-effectiveness watchdog reflects how health authorities in different parts of the world have taken different approaches with the drugs, which are the first to have shown they can slow the progression of the dis

89